Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells

Abstract

Abiraterone acetate (AA), an inhibitor of cytochrome P450 17alpha-hydroxylase/17, 20 lyase, is an FDA-approved drug for advanced prostate cancer. However, not all patients respond to AA, and AA resistance ultimately develops in patients who initially respond. We aimed to identify AA resistance mechanisms in prostate cancer cells.

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 25, 2021
Source ID
10.1158/1078-0432.ccr-20-4391

Entities

People

  • Fangfang Qu
  • Gwo-shu Mary Lee
  • Hannah Kimball
  • Konrad H Stopsack
  • Kyler Berlind
  • Philip W. Kantoff
  • Toni K Choueiri
  • Wenting Pan
  • Zhouwei Zhang

Organizations

  • Dana–Farber Cancer Institute
  • Memorial Sloan Kettering Cancer Center
  • United States Department of Defense

Tags

Fields of Study

  • Biology
  • Medicine

Readers

  • Breast cancer cell signaling and growth regulation.
  • Molecular and Cellular Biology
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.